Preimplantation Genetics Diagnosis (PGD) Market Expected to Reach $217,190.00 Thousand by 2030—Allied Market Research

According to a new report published by Allied Market Research, titled, “Preimplantation Genetics Diagnosis (PGD) Market," The preimplantation genetics diagnosis (pgd) market was valued at $81,520.20 thousand in 2020, and is estimated to reach $217,190.00 thousand by 2030, growing at a CAGR of 10.4% from 2021 to 2030. 

Depending on test type, the market is segmented on the basis of chromosomal abnormalities, aneuploidy, X-linked diseases, single gene disorders, human leukocyte antigens (HLA) typing, gender selection, and others. The chromosomal abnormalities segment accounted for the highest market share in 2020 and single gene disorders is expected to witness significant growth during the forecast period, owing to rise in number of patients suffering from genetic disorders. The market is mainly driven by increase in awareness regarding embryo genetic testing. In addition, rise in infertility rate and surge in hereditary diseases positively influenced the growth of the market. However, high costs involved for various diagnosis can hinder the growth of preimplantation genetics diagnosis market size.

In 2020, North America dominated the global PGD market, in terms of revenue, accounting for around 40% share of the radiology information system industry, followed by Europe and Asia-Pacific. Moreover, the market in Asia-Pacific is growing with high CAGR, owing to increased adoption of in vitro fertilization (IVF).

PGD is extensively used in ivf genetic testing for identification of genetic defects in embryos. PGD is effective in reducing chances of conceiving unhealthy embryos. In addition, it significantly increases the chances of successful healthy pregnancy. These factors drive the growth of the market . Furthermore, rise in infertility rate as well as genetic, hereditary, and chromosomal diseases positively influenced the growth of the market. In addition, technological advancements in PGD provide advantages, including ability to prevent disability in offspring and development of unhealthy savior siblings by using PGD with HLA. Furthermore, PGD shown positive response in patients trying to conceive with recurrent IVF failures, low sperm count, and with advance maternal age.

Furthermore, preimplantation genetics diagnosis market share is anticipated to grow rapidly throughout the forecast period, owing to increase in use of assisted reproductive technology (ART) in developed countries.

For instance, according to the U.S. Department of Health & Human Services, as of 2019, there are 489 fertility clinics in the U.S. that are involved in providing ART solutions. States including Massachusetts, Columbia, and New Jersey have the highest proportion of ART births. In addition, increase in awareness regarding healthy embryos in developing countries is expected to be a preimplantation genetic diagnosis market opportunity.

However, during the pandemic lockdown, various players in the PGD market reduced their business in countries, including China, the U.S., and India, owing to disruption of supply chain. This break directly impacted companies involved in providing PGD. In addition, extensive focus of major countries on development of vaccines negatively influenced the growth of the market. However, reopening of diagnostic facilities and introduction of vaccines for coronavirus disease boost the preimplantation genetics diagnosis market size.

The key players profiled in the PGD market report include Agilent Technologies, Inc., CeGaT GmbH, Illumina Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Natera Inc., PacGenomics, PerkinElmer, Inc., Quest Diagnostics Inc., and Reproductive Genetic Innovations (RGI).

KEY FINDINGS OF THE STUDY

• The report provides an extensive analysis of the current and emerging preimplantation genetics diagnosis market trends and dynamics. 
• Depending on test type, the chromosomal abnormalities dominated the PGD market, in terms of revenue in 2020 and the single gene disorders segment is projected to grow at a significant CAGR during the forecast period.
• Asia-Pacific is projected to register highest growth rate in the coming years.
• The key players within the PGD market are profiled in this report, and their strategies are analyzed thoroughly, which help understand competitive outlook of the PGD industry.
• The report provides an extensive analysis of the current trends and emerging opportunities of the market. 
• In-depth preimplantation genetics diagnosis market analysis is conducted by constructing estimations for the key segments between 2021 and 2030.